Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Whitehawk Therapeutics, Inc. (WHWK)
Price$4.60Cached quote
Net income
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.1M | $26.0M | $24.4M | $15.2M | $14.0M | $14.0M | $0 | $20.2M | — | — | — | — | — | — | — | — | — | — |
| Gross profit | $6.4M | $23.0M | $21.5M | $13.9M | $14.0M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross margin | 89.36% | 88.36% | 88.47% | 91.23% | 100.00% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $91.0M | $51.0M | $48.9M | $32.7M | $19.7M | $15.0M | $12.8M | $17.9M | $12.1M | $11.4M | — | — | — | — | — | — | — | — |
| Operating expenses | $121.5M | $93.4M | $96.3M | $77.9M | $112.3M | $17.1M | $24.4M | $31.3M | $21.4M | $16.6M | — | — | — | — | — | — | — | — |
| Operating income | −$114.4M | −$67.5M | −$71.9M | −$62.7M | −$111.2M | −$2.5M | −$24.4M | −$11.2M | −$21.4M | −$16.6M | −$23,006 | −$23,972 | −$22,824 | −$22,391 | −$23,585 | −$20,509 | — | — |
| Operating margin | −1,601.12% | −259.62% | −295.36% | −411.94% | −794.41% | −18.21% | — | −55.47% | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −$114.3M | −$67.3M | −$71.8M | −$62.5M | −$111.1M | −$2.5M | −$24.4M | −$11.1M | −$21.3M | −$16.6M | — | — | — | — | — | — | — | — |
| EBITDA margin | −1,600.01% | −258.88% | −294.67% | −410.90% | −793.66% | −18.14% | — | −55.24% | — | — | — | — | — | — | — | — | — | — |
| Net income | −$20.6M | −$63.7M | −$65.8M | −$60.5M | −$110.1M | −$3.5M | −$23.3M | −$10.4M | −$21.4M | −$17.0M | −$31,440 | −$30,799 | −$28,701 | −$27,365 | −$27,185 | −$22,395 | −$19,996 | −$33,623 |
| Net profit margin | −288.26% | −245.13% | −270.04% | −397.69% | −786.36% | −24.84% | — | −51.58% | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.33 | -$2.36 | -$2.44 | -$2.69 | -$12.41 | -$1.76 | -$8.55 | -$4.65 | -$15.44 | -$367.62 | -$0.15 | -$0.15 | -$0.15 | -$0.15 | -$0.15 | $0.00 | — | — |
| Diluted EPSper diluted share | -$0.33 | -$2.36 | -$2.44 | -$2.69 | -$12.41 | -$1.76 | -$8.55 | -$4.65 | -$15.44 | -$367.62 | -$0.15 | -$0.15 | -$0.15 | -$0.15 | -$0.15 | $0.00 | — | — |
Owners
Reported shareholders
8.53%of listed shares
Yu Fan4.86M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Yu Fan | 8.53%4.86M shares |
ACUTA CAPITAL PARTNERS, LLC | 8.22%4.69M shares |
QVT Financial LP | 8.10%4.62M shares |
MONTANOVA CAPITAL, LLC | 7.54%4.3M shares |
ORBIMED ADVISORS LLC | 6.90%3.93M shares |
Dalal Anupam | ≈5.98%3.41M shares |
Avoro Capital Advisors LLC | 5.00%2.85M shares |
Castelein Caley | ≈4.28%2.44M shares |
Siren, L.L.C. | 4.10%2.34M shares |
KVP Capital Advisors, LP | 3.80%2.17M shares |
BlackRock, Inc. | 3.37%1.92M shares |
Desai Neil | ≈3.18%1.81M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.44%1.39M shares |
ADAR1 Capital Management, LLC | 2.35%1.34M shares |
Zhao Baiteng | ≈2.19%1.25M shares |
ACORN CAPITAL ADVISORS, LLC | 2.00%1.14M shares |
STEMPOINT CAPITAL LP | 1.79%1.02M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.58%899.78K shares |
Ally Bridge Group (NY) LLC | 1.43%817.94K shares |
Lennon David James | ≈1.00%569.64K shares |
Percentages use 57.01M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 16, 2026Form 4 | Giacobello Scott M.CHIEF FINANCIAL OFFICER | SellCommon Stock | 141.6K | $4.13 | $584.8K | 295.2K |
| Apr 15, 2026Form 4 | Giacobello Scott M.CHIEF FINANCIAL OFFICER | SellCommon Stock | 77.0K | $3.86 | $297.2K | 436.8K |
| Apr 14, 2026Form 4 | BALL BRYANSee remarks | SellCommon Stock | 92.5K | $3.64 | $336.6K | 397.1K |
| Apr 13, 2026Form 4 | BALL BRYANSee remarks | SellCommon Stock | 26.4K | $3.46 | $91.3K | 489.6K |
| Apr 10, 2026Form 4 | BALL BRYANSee remarks | SellCommon Stock | 6.6K | $3.43 | $22.6K | 516.0K |